This study is for people with compensated cirrhosis, a liver condition where the liver is still working despite damage. It is caused by metabolic dysfunction-associated steatohepatitis (MASH), a condition where fat buildup leads to liver inflammation and scarring. The study tests if the medicine efinopegdutide can reduce liver fat, inflammation, and scarring. Researchers will also check the safety and how well people can handle this medication.

• Participants must have MASH and may or may not have controlled type 2 diabetes.
• People with other liver diseases, type 1 diabetes, or recent major illnesses cannot join.
• The study will involve regular visits, and participants may receive compensation.

If you are interested and meet the criteria, you can consider participating in this research to help find a treatment for MASH. If you are unsure about your eligibility or have questions about the study, contact the research team for more details.